Implementation of Inflation-Indexed Rebates for Part B Drugs
The Inflation Reduction Act of 2022 requires CMS to collect rebates from drug manufacturers for certain Part B drugs if prices increase faster than inflation. The implementation date of these rebate provisions is the first quarter of 2023, meaning CMS must act quickly to comply with the legislative requirements. During the past decade, OIG completed three studies that estimated how much Medicare could have saved if manufacturers had paid rebates for Part B drugs. We also summarized several implementation issues that would need to be addressed to establish rebates for Part B drugs. This product will summarize insights from OIG's previous work with the goal of assisting CMS in its implementation efforts.
|Announced or Revised||Agency||Title||Component||Report Number(s)||Expected Issue Date (FY)|
|Completed||Centers for Medicare and Medicaid Services||Implementation of Inflation-Indexed Rebates for Part B Drugs||Office of Evaluation and Inspections||OEI-BL-23-00170||2023|